Navigation Links
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Date:6/13/2008

rious infections and hypersensitivity reactions including anaphylaxis. The most common adverse events reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache and hypertension. Increases in liver function tests (ALT and AST) were seen in some patients; these increases were generally mild and reversible, with no hepatic injuries or any observed impact on liver function.

About IL-6

IL-6 is a common protein found in all joints in the body and is a natural substance that can raise inflammation. Everyone has IL-6 in their body, but people with RA may have too much. If approved, ACTEMRA will be the first and only medication to specifically target IL-6 in patients with RA.

About Rheumatoid Arthritis

Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to irreversible joint destruction and disability. Characteristics of RA include redness, swelling, pain and movement limitation around joints of the hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms of RA include fatigue, decreased hemoglobin, osteoporosis and may contribute to shortening life expectancy by affecting major organ systems. After 10 years, less than 50 percent of patients can continue to work or function normally on a daily basis. RA affects more than 21 million people worldwide with approximately 1.3 million adults affected in the United States.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative produ
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
4. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
5. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
6. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
7. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
10. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
11. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... HAIKOU, China , April 22 /PRNewswire-Asia-FirstCall/ ... (OTC Bulletin Board: KURU), a,leading bio-pharmaceutical company in ... peptide-based drugs and small molecule drugs, today,announced the signing ... of preferred stock and warrants with Caduceus Asia ...
... CardioGenics Inc. (OTC Bulletin Board: CGNH), a developer of technology and ... spotlighted in three publications during the month of April: Today,s Medical ... Transcript . , , ... the April 2010 print and online editions of Today,s ...
Cached Medicine Technology:Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 2Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 3Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement 4CardioGenics to be Spotlighted in Three Publications During Month of April 2CardioGenics to be Spotlighted in Three Publications During Month of April 3CardioGenics to be Spotlighted in Three Publications During Month of April 4
(Date:12/19/2014)... TX (PRWEB) December 20, 2014 The ... a new injectable filler from respected cosmetic brand Juvéderm. ... occur naturally with age. The Medspa at Hendrick is ... development in skin care technology to its clients. , ... gel to be FDA-approved to treat the mid-face and ...
(Date:12/19/2014)... (HealthDay News) -- All children should have their eyesight ... every year, eye experts say. The new vision-screening ... of the U.S. National Center for Children,s Vision Health. ... group require screening for eye problems, particularly vision ... ("lazy eye") and strabismus (a disorder of eye alignment). ...
(Date:12/19/2014)... -- The cost of cancer treatment can cause financial ... Researchers examined data from 1,000 people in the ... lung cancer. Of those patients, almost 900 had finished ... had advanced cancer. Nearly half of the patients ... which was linked with a poorer health-related quality of ...
(Date:12/19/2014)... Dennis Thompson HealthDay ... -- Ebola,s entrance into the United States -- along ... mumps outbreak -- have highlighted cracks in the nation,s ... new health policy report released Thursday. Half of ... respond to infectious disease outbreaks. That was the main ...
(Date:12/19/2014)... NJ (PRWEB) December 19, 2014 ... Inside Patient Care: Pharmacy & Clinics™, an independent ... healthcare team treating and caring for patients inside ... primary care expands to provide optimal access to ... offers a forum for the team treating and ...
Breaking Medicine News(10 mins):Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3
... People who suffer from the problem of excessive sweating ... have a relief from their condition. Researchers from Saint ... treatment with Botox (botulinum toxin type A) could be ... the first long-term study of repeated treatment with Botox? ...
... like learning and impulsive behavior.// ,The research, ... said that it would help shed light on the impulsive ... and his team at the University of Pittsburgh, Pennsylvania, who ... of the brain in a group of rats to examine ...
... a recent study researchers say that latest research suggests ... be ineffective for women who lack a gene called ... fertility drugs did not improve ovulation rates in mice ... The estrogen receptor beta is one of two estrogen ...
... school children from Denmark, Estonia and Portugal// reported that ... compared to children from children’s of rich and better-educated ... British Medical Journal. The results of the study challenge ... social circumstances in childhood may cause an increased risk ...
... how the heart fails, and hope that this may make ... worked to find out how the metabolic pathways differentiate in ... early stages of heart failure, the heart uses too much ... doesn't use enough fat., ,Gary Lopaschuk, a pharmacologist and ...
... registers its win against polio as the number of cases //reported ... the year 2002. , ,UNICEF, and an army of health ... leading the war against polio in India. Of the 1918 ... India alone, and 1242 cases were registered in Uttar Pradesh. This ...
Cached Medicine News:Health News:Good News For Those Suffering From Excessive Sweating 2Health News:Good News For Those Suffering From Excessive Sweating 3Health News:Regular Use Of Cocaine Can Impair Brain Functions 2Health News:New Discovery May Help Treat Infertility 2Health News:Details Of Heart Failure Discovered 2Health News:Intense Fight Against Polio In India Gets Results 2
... assays provide superior specificity, thereby reducing the ... Vironostika HIV-1 Microelisa System is an enzyme-linked ... to HIV-1 in serum, plasma or dried ... Microelisa System is an enzyme-linked immuosorbent assay ...
... The advanced performance benefits ... been applied to the ... Implants) Upper Extremity Plates. ... combine to provide a ...
The DePuy ACE Titanium Active Compression Plate offers ingenuity in the art of fracture management....
Long Handled Trephine...
Medicine Products: